Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC

NCT04193098 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer
Second-line Treatment

Interventions

BIOLOGICAL: CTL
BIOLOGICAL: Toripalimab

Sponsor

Tianjin Medical University Cancer Institute and Hospital